About us

Strategic insights: Assessing competitors' commercial strategies in the rheumatoid arthritis market.

The project reveals what drives competitors’ commercial performance and where the client can win share. It informs positioning, market access, and resource allocation decisions, focusing investment on approaches with the strongest potential to influence prescribing preference and protect revenue.

Outcome

  • Understanding of how competitors build and defend prescribing preference, distinguishing product advantages from market access conditions and commercial execution.
  • Opportunities to strengthen differentiation and customer engagement, based on unmet needs and gaps in competing offers.
  • Defined priorities for field force coverage, key account development and engagement investment.
  • Focused commercial actions to address competitive threats, including biosimilar switching, access restrictions, and competitor portfolio expansion.

KEY INTELLIGENCE OBJECTIVES

  • Map competitor portfolios and strategic priorities across originator biologics, biosimilars, and JAK inhibitors, identifying where companies pursue growth, defend established brands or shift investment.
  • Analyze positioning by patient segment and treatment line, examining how competitors use efficacy, safety, administration convenience, and clinical evidence to differentiate their products.
  • Benchmark commercial operating models, including sales team structure, territory coverage, account segmentation, targeting criteria, and performance measures.
  • Assess how competitors engage rheumatologists and other relevant stakeholders through field interactions, digital channels, congresses, and educational activities, identifying what strengthens brand preference.
  • Examine medical affairs strategies, including expert engagement, evidence generation and scientific communication, assessing their role in addressing uncertainty and shaping treatment perceptions.
  • Investigate pricing and market access approaches, including reimbursement, formulary inclusion, tender participation and contracting, assessing how treatment costs and commercial arrangements influence selection.
  • Analyze competitor approaches to treatment initiation, brand switching and retention, including patient support, administration training, and coordination with specialist nurses and pharmacies.
  • Assess how product launches, biosimilar competition, evolving treatment guidelines, and safety requirements influence competitor positioning and future commercial priorities.

Geography

  • Europe
  • Middle East
  • Africa
  • North America
  • Latin America
  • Asia-Pacific
  • Global

    • Go back to our case studies

    Get the report

    SUBSCRIBE TO MARKET MINDS

    What matters now. Subscribe to receive intelligence that helps you act before others do.

    Contact us

    Let’s start with a conversation.
    Tell us what you’re facing.

    EMBS GROUP Sp. z o.o. Sp. k., as the Data Administrator, will process the personal data provided above to respond to the message sent via the form. You can contact us at gdpr@embs-group.com or our registered office (Poland, 30-224 Kraków, Aleja Sosnowa 2a).
    The full text of the information clause is available in the Privacy Policy.
    Privacy Overview

    EMBS Group, as the Data Administrator, uses cookies to enhance user experience and analyze website traffic. You can change your cookie settings at any time. For more information, please see our Privacy Policy.